U96-CAR-T cells for relapsed B-cell leukemia and lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This early-phase trial tests a new type of immunotherapy called U96-CAR-T cells for adults with B-cell acute lymphoblastic leukemia or B-cell lymphoma that has come back or not responded to standard treatments. The treatment uses a patient's own immune cells that are modified in a lab to find and fight CD19-positive cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older with a confirmed diagnosis of B-cell acute lymphoblastic leukemia (B-ALL) or B-cell lymphoma that has returned or not responded to treatment.
- Your cancer must test positive for a protein called CD19 (detected through standard tests).
- You should have adequate organ function (heart, lungs, liver, kidneys) and blood cell counts as determined by routine lab tests.
- You cannot have other active cancers, uncontrolled infections, recent heart problems, or certain chronic infections like HIV or active hepatitis.
- Women who can become pregnant must have a negative pregnancy test and agree to use effective birth control during the study and for over a year after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy (CAR-T cells) designed to target and destroy leukemia or lymphoma cells that carry the CD19 or CD22 marker. It is for people whose cancer has not responded to other treatments or has returned.
This trial tests a 'universal' CAR-T cell therapy for B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to at least two prior treatments. The goal is to see if these special immune cells can safely find and destroy the cancer.
This trial tests a new cell therapy called CT1190B for people with certain types of B-cell lymphoma that have come back or not responded to at least two prior treatments. It aims to see if this therapy can help control the cancer.
This early-phase trial tests a type of immunotherapy called anti-CD19 CAR-T cells. These are specially engineered immune cells that seek out and destroy cancer cells with a marker called CD19 on their surface. It is for people with B-cell cancers (leukemia or lymphoma) that have not responded to or come back after standard treatments.
This trial tests a new type of CAR-T cell therapy designed to be stronger against B-cell lymphoma that has come back or not responded to previous treatments. The treatment uses your own immune cells, which are modified in a lab to better attack cancer cells.
This trial tests a personalized CAR-T cell treatment that targets a marker called CD79b in people whose B-blood cancers have come back or not responded to prior treatment. It may help your immune system find and attack cancer cells, but it also requires you to meet safety and health criteria.
Hear when a new Relapsed or Refractory B Cell Leukemia and Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.